Milan, Italy

Mattia Boeri

This inventor holds 1 USPTO granted patent and 13 published patent applications and 2 EPO patents. Top assignee: Biomirna Holdings Ltd.. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mattia Boeri. Retrieved from https://idiyas.com/inventor/mattia-boeri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mattia Boeri: Inventor in Pulmonary Tumour Biomarkers.

Introduction

Mattia Boeri is an inventor associated with Milan, Italy. His patent work focuses on micro-RNA biomarkers and their potential use in assessing and addressing pulmonary tumour risk.

Latest Patents

Boeri is associated with 1 patent, titled “Micro-RNA Biomarkers and Methods of Using Same.” The patent describes procedures and apparatus for identifying individuals at risk of pulmonary tumours or diagnosing pulmonary tumours by studying micro-RNA expression levels in blood or other biological fluids. It also describes a method and compound intended to reduce or eliminate pulmonary tumour risk by rebalancing underexpressed or overexpressed micro-RNAs.

Career Highlights

The supplied information associates Boeri with Biomirna Holdings Ltd. and Ugo Pastorino. His patent reflects an application of biomarker research to pulmonary tumour risk assessment and diagnosis.

Collaborations

Boeri’s listed collaborators include Gabriella Sozzi and Ugo Pastorino.

Conclusion

Mattia Boeri’s patent work centers on micro-RNA-based approaches to pulmonary tumour risk assessment, diagnosis, and potential risk reduction.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…